



**Urgent Field Safety Notice**  
**Molecular Diagnostics at Abbott**  
**Products:** Alinity m HBV AMP Kit and  
Alinity m HBV Application Specification File  
**List Numbers:** 08N47-090 and 08N47-01C  
**Lot Numbers:** See Appendix A

**Unique Device Identifiers (UDIs):** See Appendix A

January 12, 2023

Dear Abbott Customer,

This letter contains important information regarding the Alinity m HBV Amplification (AMP) Kit, List Number 08N47-090 utilized with the Alinity m System. Based on feedback, an update to Field Action FA-AM-MAR2022-269 is being provided to update the previously calculated carryover total. Please review this information carefully.

**Background**

Two studies were conducted to stress the overall system using study designs factoring the worst case conditions of carryover using high titer samples (100,000,000 IU/mL). Both studies processed samples through Sample Input/Processing and the AMP tray. Study 1 stressed the potential for carryover at Sample Input/Processing stages. Study 2 stressed the potential for carryover at the AMP tray. Carryover was not observed in Study 1 and was only observed in Study 2. In this updated calculation, negative samples adjacent to high titer positive samples on the AMP tray from both studies are included to calculate total carryover potential. There have been no changes to the assay or system performance since the original Field Action dated March 3, 2022. This additional information is being communicated to provide updated details on the total carryover rate and the calculated method used to determine the carryover rate.

**Potential Impact**

Below is the updated calculation for total carryover.

**Carryover**

Two studies were conducted to stress two areas of potential carryover in the system, Sample Input/Processing and the Amplification (AMP) Tray. The highest potential for carryover is at the AMP tray. Therefore, negative samples adjacent to high titer positive samples on the AMP tray from both studies are included to calculate total carryover potential.

The carryover rate for Alinity m HBV was determined by analyzing 546 valid replicates of HBV negative samples processed from alternating positions at the AMP tray with 546 valid replicates of high concentrated HBV positive samples at 100,000,000 IU/mL at the AMP tray, across multiple runs. 414 valid replicates came from negative samples in alternating positions to high titer positives at the AMP tray. 132 valid replicates came from negative samples adjacent to high titer positive samples at the Sample Input/Processing tray and the AMP tray. HBV DNA was detected in 16 of the HBV negative samples, resulting in an overall carryover rate of 2.9% (95% CI: 1.8 to 4.7%).



**Urgent Field Safety Notice**  
**Molecular Diagnostics at Abbott**  
**Products:** Alinity m HBV AMP Kit and  
Alinity m HBV Application Specification File  
**List Numbers:** 08N47-090 and 08N47-01C  
**Lot Numbers:** See Appendix A

**Unique Device Identifiers (UDIs):** See Appendix A

There is no new potential impact to results for Alinity m HBV, and there is no impact or change to the assay reagents. There have been zero (0) reports received to-date of harm associated with this issue.

**Necessary Actions**

Please complete and return the Customer Reply Form. No further action from your site is required.

This field action is to be carried out at the user / customer level. If this product has been further distributed by your facility, please notify any additional impacted customers.

The results from the Alinity m HBV assay must be interpreted within the context of all relevant clinical and laboratory findings. If results are inconsistent with patient history and other diagnostics through patient monitoring, a retest of the same sample should be considered by the physician or healthcare provider.

We continue to make progress to minimize carryover at the AMP tray. These improvements are in-process. Upon completion and appropriate agency approval, you will be contacted by a Molecular Diagnostics Abbott Representative.

We understand the importance of this change to your laboratory and are committed to continuous improvement.

Please review this information with laboratory personnel and retain this communication for future reference. If you have any questions regarding this communication, please contact your local Abbott representative. We apologize for any inconvenience this may have caused your laboratory.

Sincerely,

A handwritten signature in black ink that reads "Albert Chianello" followed by the date "Jan 12, 2022".

Albert Chianello  
Director, Quality Assurance  
Molecular Diagnostics at Abbott



**Urgent Field Safety Notice**  
**Molecular Diagnostics at Abbott**  
**Products:** Alinity m HBV AMP Kit and  
 Alinity m HBV Application Specification File  
**List Numbers:** 08N47-090 and 08N47-01C  
**Lot Numbers:** See Appendix A  
**Unique Device Identifiers (UDIs):** See Appendix A

**Appendix A**

Product Name	Part Number	Lot Impacted	UDI
Alinity m HBV Application Specification File (CE)	08N47-01C	N/A	(01)00884999048799(240)08N47-01C(8012)3.00
Alinity m HBV AMP Kit (CE)	08N47-090	380963	(01)00884999047747(10)380963(17)240715(240)08N47-090
Alinity m HBV AMP Kit (CE)	08N47-090	380979	(01)00884999047747(10)380979(17)240715(240)08N47-090
Alinity m HBV AMP Kit (CE)	08N47-090	381021	(01)00884999047747(10)381021(17)240531(240)08N47-090
Alinity m HBV AMP Kit (CE)	08N47-090	529378	(01)00884999047747(10)529378(17)230131(240)08N47-090
Alinity m HBV AMP Kit (CE)	08N47-090	529686	(01)00884999047747(10)529686(17)230131(240)08N47-090
Alinity m HBV AMP Kit (CE)	08N47-090	530272	(01)00884999047747(10)530272(17)240404(240)08N47-090
Alinity m HBV AMP Kit (CE)	08N47-090	531189	(01)00884999047747(10)531189(17)240504(240)08N47-090
Alinity m HBV AMP Kit (CE)	08N47-090	531596	(01)00884999047747(10)531596(17)240504(240)08N47-090